Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
Tokai Pharmaceuticals Identifier:
First received: August 14, 2009
Last updated: January 8, 2014
Last verified: September 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2012
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)